Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma

被引：0

作者：

Martin, Thomas ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Mikhael, Joseph ^{[3
]}

Yong, Kwee ^{[4
]}

Capra, Marcelo ^{[5
]}

Facon, Thierry ^{[6
]}

Hajek, Roman ^{[7
,8
]}

Spicka, Ivan ^{[9
]}

Casca, France ^{[10
]}

Mace, Sandrine ^{[11
]}

Risse, Marie-Laure ^{[12
]}

Moreau, Philippe ^{[13
]}

机构：

[1] Univ Calif San Francisco, Dept Hematol, San Francisco, CA USA

[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[3] Translat Genom Res Inst, City Hope Canc Ctr, Phoenix, AZ USA

[4] Univ Coll Hosp, Dept Hematol, London, England

[5] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[6] Lille Univ Hosp, Dept Hematol, Lille, France

[7] Univ Ostrava, Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[8] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[9] Charles Univ & Gen Hosp, Ist Fac Med, Dept Hematol, Dept Med, Prague, Czech Republic

[10] Ividata Life Sci Contracted Sanofi, Levallois Perret, France

[11] Sanofi R&D Translat Med, Chilly Mazarin, France

[12] Sanofi R&D, Vitry Sur Seine, France

[13] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

MM; IKEMA; isatuximab; multiple myeloma; progression-free survival; Phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-064

引用

页码：S403 / S404

页数：2

共 50 条

[41] Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data
Li, Shuo
Meng, Xiang-Yu
Maman, Souraka Tapara Dramani
Xiao, Yong-Nong
Li, Sheng
BIOMED RESEARCH INTERNATIONAL, 2018, 2018
[42] Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)
Russell, Stuart D.
Lyon, Alexander
Lenihan, Daniel J.
Moreau, Philippe
Joshua, Douglas
Chng, Wee-Joo
Palumbo, Antonio
Goldschmidt, Hartmut
Hajek, Roman
Facon, Thierry
Ludwig, Heinz
Pour, Ludek
Niesvizky, Ruben
Oriol, Albert
Rosinol, Laura
Suvorov, Aleksandr
Gaidano, Gianluca
Goranova-Marinova, Vesselina
Gillenwater, Heidi H.
Mohamed, Nehal
Feng, Shibao
Dimopoulos, Meletios A.
BLOOD, 2015, 126 (23)
[43] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Usmani, Saad Z.
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Gavriatopoulou, Maria
Oriol, Albert
Rabin, Neil
Nooka, Ajay
Qi, Ming
Beksac, Meral
Jakubowiak, Andrzej
Ding, Bifeng
Zahlten-Kumeli, Anita
Yusuf, Akeem
Dimopoulos, Meletios
LANCET ONCOLOGY, 2022, 23 (01): : 65 - 76
[44] Second-line Therapy for Patients with multiple Myeloma - almost 3 Years progression-free Survival with Combination of Isatuximab, Proteasome Inhibitor and Dexamethasone
不详
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
[45] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial
Stewart, A. Keith
Siegel, David
Ludwig, Heinz
Facon, Thierry
Goldschmidt, Hartmut
Jakubowiak, Andrzej J.
Miguel, Jesus F. San
Obreja, Mihaela
Blaedel, Julie
Dimopoulos, Meletios A.
BLOOD, 2017, 130
[46] Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials
Mangal, Naveen
Salem, Ahmed Hamed
Menon, Rajeev M.
Freise, Kevin J.
HEMATOLOGICAL ONCOLOGY, 2018, 36 (03) : 547 - 553
[47] Depth of response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in front-line induction of high-risk Multiple Myeloma: Interim analysis of the GMMG-CONCEPT trial
Weisel, K. C.
Asemissen, A. M.
Leypoldt, L.
Besemer, B.
Haenel, M.
Blau, I. W.
Goerner, M.
Ko, Y. -D.
Duerig, J.
Staib, P.
Mann, C.
Lutz, R.
Munder, M.
Graeven, U.
Peceny, R.
Salwender, H.
Zago, M.
Benner, A.
Tichy, D.
Bokemeyer, C.
Goldschmidt, H.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 91 - 92
[48] MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Touzeau, Cyrille
Hungria, Vania T. M.
Bhutani, Divaya
Landgren, Ola
Vieyra, Diego
Guo, Yue
Verona, Raluca
Miao, Xin
Qi, Mia
Watkins, Latisha
Shah, Priya
Chastain, Katherine
Qi, Ming
Quach, Hang
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial
Kazandjian, Dickran
Korde, Neha
Mailankody, Sham
Hill, Elizabeth
Figg, William D.
Roschewski, Mark
Landgren, Ola
JAMA ONCOLOGY, 2018, 4 (12) : 1781 - 1783
[50] Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1
Bringhen, Sara
Voorhees, Peter M.
Plesner, Torben
Mellqvist, Ulf-Henrik
Reeves, Brandi
Sonneveld, Pieter
Byrne, Catriona
Nordstrom, Eva
Harmenberg, Johan
Obermueller, Jakob
Richardson, Paul G.
BLOOD, 2019, 134

← 1 2 3 4 5 →